The present disclosure relates generally to pharmaceuticals. More 5 specifically, thedisclosure is directed to a formulation comprising nano-structured lipid carrierparticles with a core comprising of a) a solid lipid; b) a liquid lipid; c) berberine orits pharmaceutically acceptable salts; d) a cationic component and e) anemulsifying agent; wherein the core has a coating comprising zinc. The disclosure10 further relates to methods of preparation of said formulations. The formulationenhances bioavailability and gives a controlled release profile of insolubleberberine in the physiological environment.
Arun Kumar, Tapan Behl, Sumit Jamwal